<p>宾夕法尼亚州马尔文，2026 年 5 月 19 日（GLOBE NEWSWIRE）—— Annovis Bio, Inc.（纽约证券交易所代码：ANVS）（“Annovis” 或 “公司”）是一家处于第三阶段临床阶段的生物技术公司，正在开发用于阿尔茨海默病（AD）和帕金森病（PD）等神经退行性疾病的实验性口服疗法 buntanetap，今天宣布了一项拟议的承销公开发行，计划提供和出售（i）其普通股股份和（ii）附带的购买普通股股份的认股权证。普通股股份和附带的认股权证将单独发行，但只能在拟议的发行中一起购买。所有普通股股份和附带的认股权证将由 Annovis 提供。拟议的发行受市场和其他条件的影响，无法保证发行是否会完成或何时完成，或发行的实际规模或条款。</p>
<p>Canaccord Genuity 担任此次发行的唯一账簿管理人。</p>
<p>Annovis 计划将此次发行的净收益用于其主要化合物 buntanetap 在阿尔茨海默病（AD）第三阶段研究中的持续临床开发，以及用于营运资金和一般公司用途。</p>
<p>普通股股份和附带的认股权证由 Annovis 根据之前于 2024 年 2 月 1 日向证券交易委员会（SEC）提交并于 2024 年 2 月 12 日获得 SEC 批准的有效货架注册声明（编号：333-276814）进行发行。关于拟议发行条款的初步招股说明书补充及相关招股说明书将提交给 SEC。初步招股说明书补充及相关招股说明书的副本可从以下地址获取：Canaccord Genuity LLC，注意：联合部门，波士顿，马萨诸塞州邮政广场 1 号，30 楼，邮政编码 02109，或通过电子邮件联系 prospectus@cgf.com。初步招股说明书补充及相关招股说明书的电子副本也将在 SEC 的网站上提供，网址为 http://www.sec.gov。</p>
<p>本新闻稿不构成出售证券的要约或购买证券的要约邀请，也不应在任何州或其他司法管辖区进行证券的出售，若该要约、邀请或出售在该州或其他司法管辖区的证券法下是非法的，除非已进行注册或资格认证。</p>
<p><strong>关于 Annovis</strong></p>
<p>Annovis Bio, Inc.（纽约证券交易所代码：ANVS）总部位于宾夕法尼亚州马尔文，是一家处于第三阶段临床阶段的生物技术公司，开发用于阿尔茨海默病（AD）和帕金森病（PD）等神经退行性疾病的治疗。公司的主要药物候选者 buntanetap（前称 posiphen）是一种实验性每日一次的口服疗法，通过特定的 RNA 靶向机制抑制多种神经毒性蛋白的翻译，包括 APP 和淀粉样β、tau、α-突触核蛋白和 TDP-43。通过解决神经退行性疾病的根本原因，Annovis 旨在阻止疾病进展并改善患者的认知和运动功能。有关更多信息，请访问 www.annovisbio.com，并在 LinkedIn、YouTube 和 X 上关注我们。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1933 年证券法和 1934 年证券交易法（修订版）规定的前瞻性声明，包括但不限于关于发行完成、满足交割条件和拟议发行收益使用的声明。实际结果可能因各种风险和不确定性而有所不同，包括公司在其年度报告（表格 10-K）和季度报告（表格 10-Q）中列出的 “风险因素” 中概述的风险。除法律要求外，公司不承担更新前瞻性声明的义务。</p>
<p><strong>联系信息：</strong></p>
<p>Annovis Bio Inc.</p>
<p>101 Lindenwood Drive</p>
<p>Suite 225</p>
<p>Malvern, PA 19355</p>
<p>www.annovisbio.com</p>
<p><strong>投资者联系：</strong></p>
<p>亚历山大·莫林，博士</p>
<p>战略传播总监</p>
<p>Annovis Bio</p>
<p>ir@annovisbio.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU16TTFNU00zTmpFeU1ESXlJekl4T1RRNE5UQT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU16TTFNU00zTmpFeU1ESXlJekl4T1RRNE5UQT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjY5YWFmN2UtZWNmOC00OGQwLThmYmYtZDEzMDY2ODhjMmVlLTEyMDY0MDMtMjAyNi0wNS0xOS1lbg==/tiny/Annovis-Bio-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjY5YWFmN2UtZWNmOC00OGQwLThmYmYtZDEzMDY2ODhjMmVlLTEyMDY0MDMtMjAyNi0wNS0xOS1lbg==/tiny/Annovis-Bio-Inc-.png"/></p>

生物科技ETF基金

2 倍做多纳斯达克生物技术 ETF - ProShares

汇添富纳斯达克生物科技ETF

<p>Annovis Bio, Inc. 宣布计划进行一次承销的公开发行普通股及相关认股权证。此次发行旨在为其主要化合物 buntanetap 在阿尔茨海默病和帕金森病的临床开发筹集资金。Canaccord Genuity 是唯一的账簿管理人。此次发行受市场条件的影响，具体细节将在提交给美国证券交易委员会（SEC）的初步招股说明书中列出</p>

<p>MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) accompanying warrants to purchase shares of common stock. The shares of common stock and the accompanying warrants will be issued separately but can only be purchased together in the proposed offering. All of the shares of common stock and the accompanying warrants will be offered by Annovis. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p>
<div class="lb-trans"><p>宾夕法尼亚州马尔文，2026 年 5 月 19 日（GLOBE NEWSWIRE）—— Annovis Bio, Inc.（纽约证券交易所代码：ANVS）（“Annovis” 或 “公司”）是一家处于第三阶段临床阶段的生物技术公司，正在开发用于阿尔茨海默病（AD）和帕金森病（PD）等神经退行性疾病的实验性口服疗法 buntanetap，今天宣布了一项拟议的承销公开发行，计划提供和出售（i）其普通股股份和（ii）附带的购买普通股股份的认股权证。普通股股份和附带的认股权证将单独发行，但只能在拟议的发行中一起购买。所有普通股股份和附带的认股权证将由 Annovis 提供。拟议的发行受市场和其他条件的影响，无法保证发行是否会完成或何时完成，或发行的实际规模或条款。</p>
</div><p>Canaccord Genuity is acting as the sole bookrunner in the offering.</p>
<div class="lb-trans"><p>Canaccord Genuity 担任此次发行的唯一账簿管理人。</p>
</div><p>Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound buntanetap in a Phase 3 study for Alzheimer’s disease (AD), and for working capital and general corporate purposes.</p>
<div class="lb-trans"><p>Annovis 计划将此次发行的净收益用于其主要化合物 buntanetap 在阿尔茨海默病（AD）第三阶段研究中的持续临床开发，以及用于营运资金和一般公司用途。</p>
</div><p>The shares and the accompanying warrants are being offered by Annovis pursuant to an effective shelf registration statement on Form S-3 (No. 333-276814) previously filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, 30th Floor, Boston, Massachusetts 02109, or by email at prospectus@cgf.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the SEC’s website at http://www.sec.gov.</p>
<div class="lb-trans"><p>普通股股份和附带的认股权证由 Annovis 根据之前于 2024 年 2 月 1 日向证券交易委员会（SEC）提交并于 2024 年 2 月 12 日获得 SEC 批准的有效货架注册声明（编号：333-276814）进行发行。关于拟议发行条款的初步招股说明书补充及相关招股说明书将提交给 SEC。初步招股说明书补充及相关招股说明书的副本可从以下地址获取：Canaccord Genuity LLC，注意：联合部门，波士顿，马萨诸塞州邮政广场 1 号，30 楼，邮政编码 02109，或通过电子邮件联系 prospectus@cgf.com。初步招股说明书补充及相关招股说明书的电子副本也将在 SEC 的网站上提供，网址为 http://www.sec.gov。</p>
</div><p>This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售证券的要约或购买证券的要约邀请，也不应在任何州或其他司法管辖区进行证券的出售，若该要约、邀请或出售在该州或其他司法管辖区的证券法下是非法的，除非已进行注册或资格认证。</p>
</div><p><strong>About Annovis</strong></p>
<div class="lb-trans"><p><strong>关于 Annovis</strong></p>
</div><p>Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.</p>
<div class="lb-trans"><p>Annovis Bio, Inc.（纽约证券交易所代码：ANVS）总部位于宾夕法尼亚州马尔文，是一家处于第三阶段临床阶段的生物技术公司，开发用于阿尔茨海默病（AD）和帕金森病（PD）等神经退行性疾病的治疗。公司的主要药物候选者 buntanetap（前称 posiphen）是一种实验性每日一次的口服疗法，通过特定的 RNA 靶向机制抑制多种神经毒性蛋白的翻译，包括 APP 和淀粉样β、tau、α-突触核蛋白和 TDP-43。通过解决神经退行性疾病的根本原因，Annovis 旨在阻止疾病进展并改善患者的认知和运动功能。有关更多信息，请访问 www.annovisbio.com，并在 LinkedIn、YouTube 和 X 上关注我们。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the consummation of the offering, the satisfaction of closing conditions and the intended use of proceeds from the offering. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1933 年证券法和 1934 年证券交易法（修订版）规定的前瞻性声明，包括但不限于关于发行完成、满足交割条件和拟议发行收益使用的声明。实际结果可能因各种风险和不确定性而有所不同，包括公司在其年度报告（表格 10-K）和季度报告（表格 10-Q）中列出的 “风险因素” 中概述的风险。除法律要求外，公司不承担更新前瞻性声明的义务。</p>
</div><p><strong>Contact Information:</strong></p>
<div class="lb-trans"><p><strong>联系信息：</strong></p>
</div><p>Annovis Bio Inc.</p>
<div class="lb-trans"><p>Annovis Bio Inc.</p>
</div><p>101 Lindenwood Drive</p>
<div class="lb-trans"><p>101 Lindenwood Drive</p>
</div><p>Suite 225</p>
<div class="lb-trans"><p>Suite 225</p>
</div><p>Malvern, PA 19355</p>
<div class="lb-trans"><p>Malvern, PA 19355</p>
</div><p>www.annovisbio.com</p>
<div class="lb-trans"><p>www.annovisbio.com</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>Alexander Morin, Ph.D.</p>
<div class="lb-trans"><p>亚历山大·莫林，博士</p>
</div><p>Director, Strategic Communications</p>
<div class="lb-trans"><p>战略传播总监</p>
</div><p>Annovis Bio</p>
<div class="lb-trans"><p>Annovis Bio</p>
</div><p>ir@annovisbio.com</p>
<div class="lb-trans"><p>ir@annovisbio.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU16TTFNU00zTmpFeU1ESXlJekl4T1RRNE5UQT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcyMzM1MSM3NjEyMDIyIzIxOTQ4NTA="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjY5YWFmN2UtZWNmOC00OGQwLThmYmYtZDEzMDY2ODhjMmVlLTEyMDY0MDMtMjAyNi0wNS0xOS1lbg==/tiny/Annovis-Bio-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MjY5YWFmN2UtZWNmOC00OGQwLThmYmYtZDEzMDY2ODhjMmVlLTEyMDY0MDMtMjAyNi0wNS0xOS1lbg==/tiny/Annovis-Bio-Inc-.png"/></p>

Annovis 宣布启动拟议的普通股及附带认股权证的公开发行 | ANVS 股票新闻